Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arja Harila-Saari is active.

Publication


Featured researches published by Arja Harila-Saari.


Genome Biology | 2013

Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia

Jessica Nordlund; Christofer Bäcklin; Per Wahlberg; Stephan Busche; Eva C Berglund; Maija-Leena Eloranta; Trond Flægstad; Erik Forestier; Britt-Marie Frost; Arja Harila-Saari; Mats Heyman; Olafur G. Jonsson; Rolf Larsson; Josefine Palle; Lars Rönnblom; Kjeld Schmiegelow; Daniel Sinnett; Stefan Söderhäll; Tomi Pastinen; Mats G. Gustafsson; Gudmar Lönnerholm; Ann-Christine Syvänen

BackgroundAlthough aberrant DNA methylation has been observed previously in acute lymphoblastic leukemia (ALL), the patterns of differential methylation have not been comprehensively determined in all subtypes of ALL on a genome-wide scale. The relationship between DNA methylation, cytogenetic background, drug resistance and relapse in ALL is poorly understood.ResultsWe surveyed the DNA methylation levels of 435,941 CpG sites in samples from 764 children at diagnosis of ALL and from 27 children at relapse. This survey uncovered four characteristic methylation signatures. First, compared with control blood cells, the methylomes of ALL cells shared 9,406 predominantly hypermethylated CpG sites, independent of cytogenetic background. Second, each cytogenetic subtype of ALL displayed a unique set of hyper- and hypomethylated CpG sites. The CpG sites that constituted these two signatures differed in their functional genomic enrichment to regions with marks of active or repressed chromatin. Third, we identified subtype-specific differential methylation in promoter and enhancer regions that were strongly correlated with gene expression. Fourth, a set of 6,612 CpG sites was predominantly hypermethylated in ALL cells at relapse, compared with matched samples at diagnosis. Analysis of relapse-free survival identified CpG sites with subtype-specific differential methylation that divided the patients into different risk groups, depending on their methylation status.ConclusionsOur results suggest an important biological role for DNA methylation in the differences between ALL subtypes and in their clinical outcome after treatment.


Journal of Clinical Oncology | 2007

Scholastic Achievements of Childhood Leukemia Patients: A Nationwide, Register-Based Study

Arja Harila-Saari; Päivi M. Lähteenmäki; Eero Pukkala; Pentti Kyyrönen; Marjatta Lanning; Risto Sankila

PURPOSE Studies concerning the scholastic achievement of survivors of childhood leukemia have yielded controversial results. We studied the school marks of childhood leukemia survivors in a register-based study. PATIENTS AND METHODS Three hundred seventy-one patients with a diagnosis of leukemia before the age of 16 years who were born between 1974 and 1986 and alive on their 16th birthday were identified from the Finnish Cancer Registry. Five matched controls were sought for each patient from the Population Register Center of Finland. Information on the ninth-grade school report was obtained from Statistics Finland. The overall mark average and the marks (scale 4 to 10) for mother tongue, foreign language, mathematics, and physical education were compared between the patients and controls. RESULTS The ninth-grade school report was obtained by 97.6% of the patients and 98.5% of the controls. The patients whose treatment included cranial irradiation had a lower overall mark average (mean difference, -0.24; 95% CI, -0.33 to -0.15) and lower marks for all assessed school subjects compared with their controls. Of the patients treated with chemotherapy alone, only the females with leukemia diagnosed before 7 years of age had lower school marks than their controls. The biggest difference was observed in the marks for foreign language among the irradiated females diagnosed at a young age (mean difference, -1.0; 95% CI, -1.25 to -0.74). CONCLUSION Leukemia treatment that includes cranial irradiation impairs scholastic achievement. It is noteworthy that treatment of leukemia with chemotherapy alone impairs school performance only in females diagnosed before school age.


Haematologica | 2008

Acute lymphoblastic leukemia in adolescents and young adults in Finland

Anu Usvasalo; Riikka Räty; Sakari Knuutila; Kim Vettenranta; Arja Harila-Saari; Esa Jantunen; Marjut Kauppila; Pirjo Koistinen; Katriina Parto; Pekka Riikonen; Toivo T. Salmi; Raija Silvennoinen; Erkki Elonen; Ulla M. Saarinen-Pihkala

Recent reports indicate that adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric rather than adult therapeutic protocols. This Finnish study did not show any major difference between patients treated with pediatric protocols and those treated with adult protocols, but confirmed that adolescents and young adults with acute lymphoblastic leukemia still have a poorer outcome than children below 10 years of age. See related perspective article on page 1124. Background Interest has recently been paid to adolescents and young adults with acute lymphoblastic leukemia, particularly because all reports so far published indicate that these patients have a better outcome when treated with pediatric rather than adult therapeutic protocols. There are different biological subtypes of acute lymphoblastic leukemia with distinct features and prognoses; the distribution of these subtypes is not well known among adolescents. We, therefore, studied acute lymphoblastic leukemia in adolescents and young adults aged 10 to 25 years in Finland. Design and Methods This population-based study included 225 consecutive patients aged 10–25 years diagnosed with acute lymphoblastic leukemia during 1990–2004. One hundred and twenty-eight patients (10–16 years) were treated with pediatric Nordic (NOPHO) protocols, and 97 patients (17–25 years) with Finnish Leukemia Group National protocols. We characterized the biological subtypes, clinical features and outcome of these patients. Results For the whole cohort, the remission rate was 96%, 5-year event-free survival 62% and overall survival 72%.The 5-year event-free survival was 67% for the pediatric treatment group and 60% for the adult treatment group (p=n.s.). Patients with inferior outcome were those with a white bood cell count ≥ 100×109/L, the Philadelphia chromosome and MLL. Good prognostic features were TEL-AML1, hyperdiploidy, and pediatric intermediate risk stratification. Conclusions Unlike all previous studies, we found that the outcome of adolescents and young adults with acute lymphoblastic leukemia treated with pediatric or adult therapeutic protocols was comparable. The success of the adult acute lymphoblastic leukemia therapy emphasizes the benefit of central referral of patients to academic centers and adherence to research protocols. Key words: acute lymphoblastic leukemia, adolescents, survival, treatment outcome, young adults.


Journal of Clinical Oncology | 2007

High Body Mass Index Increases the Risk for Osteonecrosis in Children With Acute Lymphoblastic Leukemia

Riitta Niinimäki; Arja Harila-Saari; Airi Jartti; Raija M. Seuri; Pekka Riikonen; Eija Pääkkö; Merja Möttönen; Marjatta Lanning

PURPOSE The aim of the study was to determine the incidence of and clinical risk factors for radiographic osteonecrosis (ON) in children treated for acute lymphoblastic leukemia (ALL) using the Nordic ALL protocols. PATIENTS AND METHODS Ninety-seven consecutive patients with childhood ALL were studied prospectively by magnetic resonance imaging (MRI) of the lower extremities at the end of the treatment. RESULTS Twenty-three (24%) of the 97 patients had ON. Seven of the patients (30%) were symptomatic, and three patients (13%) required surgical interventions. Multiple logistic regression analysis showed that high body mass index (BMI; P = .04), female sex (P = .01), older age at diagnosis (P < .001), and higher cumulative dexamethasone dose (P = .03) were independent risk factors for radiographic ON. The cumulative prednisone dose did not differ significantly between the patients with and without ON. The incidence of radiographic ON decreased significantly, from 36% to 7%, when the duration of dexamethasone exposure during the delayed-intensification phase was shortened from 3 to 4 weeks to 2 weeks with a taper (P = .001). CONCLUSION ON as determined by MRI was found to be a common complication in children and adolescents after treatment with the Nordic ALL protocols. Revision of the ALL protocols by shortening the single exposure to dexamethasone has diminished the risk for ON remarkably. High BMI was identified as a new significant risk factor for ON.


Neuro-oncology | 2009

Radiation-induced meningiomas: A shadow in the success story of childhood leukemia

Joanna S. Banerjee; Eija Pääkkö; Marika J. Harila; Riitta Herva; Juho Tuominen; Antero Koivula; Marjatta Lanning; Arja Harila-Saari

While the prognosis of acute childhood leukemia has improved, long-term survivors are increasingly experiencing late effects of the treatment. Cranially irradiated survivors are predisposed to the development of CNS tumors. Our aim was to describe the incidence of secondary brain tumors and to define the significance of treatment-related risk factors and host characteristics in a cohort of childhood leukemia survivors. Our cohort consisted of 60 consecutive cranially irradiated adult survivors of childhood leukemia treated in Oulu University Hospital (Oulu, Finland); MRI of the brain was performed on 49. The sites of the tumors, their histology, and details of the leukemia treatment were determined. Of the 49 patients, 11 (22%) 1-8 years of age at the time of diagnosis developed meningioma later in life, while no other brain tumors were seen. In this cohort, the development of meningioma seemed to show undisputable linkage with long latency periods (mean, 25 years; range, 14-34 years) and an increasing incidence 20 years after the treatment (47%). Three patients had multiple meningiomas, two had recurrent disease, and one had an atypical meningioma. Age at the time of irradiation, gender, or cumulative doses of chemotherapeutic agents showed no significant association with the development of meningiomas. The high incidence of meningiomas in this study was associated with long follow-up periods. Although the cohort is small, it seems probable that the increasing incidence of meningioma will shadow the future of cranially irradiated leukemia survivors. Systematic brain imaging after the treatment is therefore justifiable.


Pediatric Blood & Cancer | 2011

Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia.

Bendik Lund; Ann Åsberg; Mats Heyman; Jukka Kanerva; Arja Harila-Saari; Henrik Hasle; Stefan Söderhäll; Olafur G. Jonsson; Stian Lydersen; Kjeld Schmiegelow

In spite of major improvements in the cure rate of childhood acute lymphoblastic leukaemia (ALL), 2–4% of patients still die from treatment related complications.


Pediatric Blood & Cancer | 2009

Progressive neurocognitive impairment in young adult survivors of childhood acute lymphoblastic leukemia

Marika J. Harila; Satu Winqvist; Marjatta Lanning; Risto Bloigu; Arja Harila-Saari

Despite the extensive literature on neuropsychological sequelae after treatment of childhood acute lymphoblastic leukemia (ALL), the very‐long‐term neurocognitive outcome of the survivors is poorly studied. We assessed neuropsychological functioning in a population‐based cohort of young adult childhood ALL survivors.


British Journal of Haematology | 2014

Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.

Raheel Altaf Raja; Kjeld Schmiegelow; Birgitte Klug Albertsen; Kaie Prunsild; Bernward Zeller; Goda Vaitkeviciene; Jonas Abrahamsson; Mats Heyman; Mervi Taskinen; Arja Harila-Saari; Jukka Kanerva; Thomas L. Frandsen

L‐asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL). Treatment is associated with several toxicities, including acute pancreatitis. Clinical course, presentation, re‐exposure to L‐asparginase after pancreatitis and risk of recurrent pancreatitis within an asparaginase‐intensive protocol has been poorly reported. Children (1–17 years) on the ongoing Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol with asparaginase‐associated pancreatitis (AAP) diagnosed between 2008 and 2012 were identified through the online NOPHO ALL toxicity registry. NOPHO ALL2008 includes eight or 15 doses of intramuscular pegylated L‐asparginase (PEG‐asparaginase) 1000 iu/m2/dose at 2–6 weeks intervals, with a total of 30 weeks of exposure to PEG‐asparaginase (clinicaltrials.gov no: NCT00819351). Of 786 children, 45 were diagnosed with AAP with a cumulative risk of AAP of 5·9%. AAP occurred after a median of five doses (range 1–13), and 11 d (median) from the latest administration of PEG‐Asparaginase. Thirteen patients developed pseudocysts (30%) and 11 patients developed necrosis (25%). One patient died from pancreatitis. Twelve AAP patients were re‐exposed to L‐asparginase, two of whom developed mild AAP once more, after four and six doses respectively. In conclusion, re‐exposure to PEG‐asparaginase in ALL patients with mild AAP seems safe.


Pediatric Blood & Cancer | 2010

High health‐related quality of life among long‐term survivors of childhood acute lymphoblastic leukemia

Marika J. Harila; Jarmo Salo; Marjatta Lanning; Ilpo Vilkkumaa; Arja Harila-Saari

Health‐related quality of life (HRQoL) was assessed in a cohort of long‐term childhood acute lymphoblastic leukemia (ALL) survivors.


European Journal of Haematology | 2012

Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia

Mette Levinsen; Diana Shabaneh; Cathrine Bohnstedt; Arja Harila-Saari; Olafur G. Jonsson; Jukka Kanerva; Anna Lindblom; Bendik Lund; Elisabeth Wreford Andersen; Kjeld Schmiegelow

Trimethoprim‐sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP). We explored to which extent TMP/SMX influenced methotrexate (MTX)/6‐mercaptopurine (6MP) dosage, myelosuppression, and event‐free survival (EFS) during maintenance therapy. Of 447 study patients treated by the NOPHO ALL92 protocol, 120 patients received TMP/SMX continuously for 2–7 d/wk (TMP/SMX2–7) and 287 patients never received TMP/SMX (TMP/SMXnever). Ten patients (all TMP/SMXnever) developed PCP, eight of which occurred within 7 months from the start of maintenance therapy. The TMP/SMX2–7 group received lower oral 6MP doses than TMP/SMXnever patients (50.6 vs. 63.9 mg/m2/d; P < 0.001) but had lower absolute neutrophil counts (ANC) (median 1.7 vs. 2.0 × 109/L; P < 0.001). In Cox multivariate analysis, higher ANC levels (P = 0.04) and male gender (P = 0.06) were related to reduced EFS. ANC had no effect on EFS among TMP/SMX2–7 patients (P = 0.40) but did for TMP/SMXnever patients (P = 0.02). The difference in the effect on EFS between TMP/SMX2–7 and TMP/SMXnever patients was not significant (P = 0.46). EFS did not differ between TMP/SMX2–7 and TMP/SMXnever patients (0.83 vs. 0.83; P = 0.82). These results suggest that TMP/SMX is effective in preventing PCP and may have an antileukemic effect. TMP/SMX should be given the entire duration of maintenance therapy.

Collaboration


Dive into the Arja Harila-Saari's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mats Heyman

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar

Olafur G. Jonsson

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mette Levinsen

Copenhagen University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stefan Söderhäll

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge